CN103340899A - 包括三氧化二砷的口服组合物的制剂及其使用方法 - Google Patents

包括三氧化二砷的口服组合物的制剂及其使用方法 Download PDF

Info

Publication number
CN103340899A
CN103340899A CN2013101363192A CN201310136319A CN103340899A CN 103340899 A CN103340899 A CN 103340899A CN 2013101363192 A CN2013101363192 A CN 2013101363192A CN 201310136319 A CN201310136319 A CN 201310136319A CN 103340899 A CN103340899 A CN 103340899A
Authority
CN
China
Prior art keywords
arsenic trioxide
solution
arsenic
oral
leukemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013101363192A
Other languages
English (en)
Chinese (zh)
Inventor
C·R·库马纳
Y·邝
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Versitech Ltd
Original Assignee
Versitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Versitech Ltd filed Critical Versitech Ltd
Publication of CN103340899A publication Critical patent/CN103340899A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2013101363192A 2002-10-09 2003-10-08 包括三氧化二砷的口服组合物的制剂及其使用方法 Pending CN103340899A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US41720002P 2002-10-09 2002-10-09
US60/417,200 2002-10-09
US48301403P 2003-06-25 2003-06-25
US60/483,014 2003-06-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN 200380105498 Division CN1723029A (zh) 2002-10-09 2003-10-08 包括三氧化二砷的口服组合物的制剂及其使用方法

Publications (1)

Publication Number Publication Date
CN103340899A true CN103340899A (zh) 2013-10-09

Family

ID=32096185

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2013101363192A Pending CN103340899A (zh) 2002-10-09 2003-10-08 包括三氧化二砷的口服组合物的制剂及其使用方法

Country Status (6)

Country Link
US (1) US7521071B2 (cg-RX-API-DMAC7.html)
EP (2) EP1562616B1 (cg-RX-API-DMAC7.html)
JP (1) JP4786341B2 (cg-RX-API-DMAC7.html)
CN (1) CN103340899A (cg-RX-API-DMAC7.html)
AU (1) AU2003271510A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004032822A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10111836B2 (en) 2015-02-01 2018-10-30 Orsenix Holdings Bv High surface-area lyophilized compositions comprising arsenic for oral administration in patients
CN111184703A (zh) * 2018-11-15 2020-05-22 哈尔滨医大药业股份有限公司 三氧化二砷缓释小丸及其制备方法

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1044559C (zh) * 1995-08-23 1999-08-11 哈尔滨医科大学附属第一医院 抗白血病、肝癌、淋巴瘤注射液
US8906422B2 (en) * 2002-10-09 2014-12-09 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US20080166425A1 (en) * 2002-10-09 2008-07-10 The University Of Hong Kong Method for inhibiting cancer using arsenic trioxide
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
US20080089949A1 (en) * 2006-10-13 2008-04-17 Yok-Lam Kwong Method for treating cancer using oral arsenic trioxide
US20110008327A1 (en) 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100028339A1 (en) 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
CN1984663A (zh) 2004-03-29 2007-06-20 南佛罗里达大学 用曲西瑞宾和相关化合物有效治疗肿瘤和癌症
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
US20080089951A1 (en) * 2006-10-11 2008-04-17 The University Of Hong Kong Method for Inhibiting Cancer Using Arsenic Trioxide
US8795738B2 (en) 2009-11-12 2014-08-05 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
US8834938B2 (en) 2011-05-18 2014-09-16 Board Of Regents Of The University Of Texas System Use of arsenic for cancer therapy protection
CN103142648B (zh) * 2011-12-07 2015-04-15 浙江中医药大学 一种砷化合物溶液及其制备的包载砷化合物的白蛋白纳米粒和冻干制剂
EP2897906B1 (en) 2012-09-20 2017-07-05 Bendale, Yogesh Narayan Process for bio synthesis of nano arsenic trioxide and its use in treatment of diseases including cancers
US20160015743A1 (en) * 2013-03-15 2016-01-21 Rush University Medical Center Methods for treating cancer
PL3250213T3 (pl) * 2015-01-29 2023-10-30 Eupharma Pty Ltd Kompozycje zawierające arsen do stosowania w sposobach leczenia
KR102015858B1 (ko) * 2015-10-23 2019-08-30 손영태 법제된 비상을 함유하는 면역력 증강을 위한 약학적 조성물
AU2017368444B9 (en) 2016-12-01 2020-07-02 Eupharma Pty Ltd Arsenic compositions
US11583552B2 (en) 2021-02-17 2023-02-21 Manoj Maniar Pharmaceutical formulation of arsenic trioxide
EP4455672A1 (en) 2023-04-26 2024-10-30 Medsenic Method and kit for diagnosing and monitoring chronic graft-versus-host disease (cgvhd) using particular cytokine biomarkers
AU2025223378A1 (en) 2024-02-14 2026-07-30 Assistance Publique - Hôpitaux De Paris Oral composition of arsenic trioxide for cancer treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1285743A (zh) * 1997-11-10 2001-02-28 斯隆-凯特林纪念癌症中心 三氧化二砷制剂生产法及用三氧化二砷或米拉索普治癌法
CN1370540A (zh) * 2001-02-15 2002-09-25 暨南大学 治疗恶性淋巴瘤的药物及其配制方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1391206B1 (en) * 1997-10-15 2008-07-02 Polarx Biopharmaceuticals, Inc. Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma
FR2786103A1 (fr) * 1998-10-30 2000-05-26 Assist Publ Hopitaux De Paris Utilisation de trioxyde d'arsenic pour la preparation d'un medicament destine a traiter les affections neoplastiques du tissu hematopoietique chez un mammifere et nouvelle composition pharmaceutique
US7521071B2 (en) * 2002-10-09 2009-04-21 Versitech Limited Formulation of oral compositions comprising arsenic trioxide and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1285743A (zh) * 1997-11-10 2001-02-28 斯隆-凯特林纪念癌症中心 三氧化二砷制剂生产法及用三氧化二砷或米拉索普治癌法
CN1370540A (zh) * 2001-02-15 2002-09-25 暨南大学 治疗恶性淋巴瘤的药物及其配制方法

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10111836B2 (en) 2015-02-01 2018-10-30 Orsenix Holdings Bv High surface-area lyophilized compositions comprising arsenic for oral administration in patients
US10272045B2 (en) 2015-02-01 2019-04-30 Orsenix Holdings Bv High surface-area lyophilized compositions comprising arsenic for oral administration in patients
US10653628B2 (en) 2015-02-01 2020-05-19 Orsenix Holdings Bv High surface-area lyophilized compositions comprising arsenic for oral administration in patients
US12364664B2 (en) 2015-02-01 2025-07-22 Quetzal Therapeutics, Llc Lyophilized compositions comprising arsenic
CN111184703A (zh) * 2018-11-15 2020-05-22 哈尔滨医大药业股份有限公司 三氧化二砷缓释小丸及其制备方法

Also Published As

Publication number Publication date
JP2006503109A (ja) 2006-01-26
US20040126434A1 (en) 2004-07-01
US7521071B2 (en) 2009-04-21
AU2003271510A1 (en) 2004-05-04
JP4786341B2 (ja) 2011-10-05
AU2003271510A8 (en) 2004-05-04
EP1562616B1 (en) 2016-06-01
EP3106169B1 (en) 2021-05-19
WO2004032822A3 (en) 2004-12-29
EP3106169A1 (en) 2016-12-21
EP1562616A4 (en) 2008-12-17
WO2004032822A2 (en) 2004-04-22
EP1562616A2 (en) 2005-08-17

Similar Documents

Publication Publication Date Title
US7521071B2 (en) Formulation of oral compositions comprising arsenic trioxide and methods of use thereof
US9125884B2 (en) Methods for treating cancers using oral formulations of cytidine analogs
KR100790589B1 (ko) 암 치료용 조성물 및 치료 방법
JP7539855B2 (ja) 患者の経口投与のためのヒ素を含む高表面積の凍結乾燥組成物
JP2020528880A (ja) 併用がん療法
CN106604745A (zh) 使用胞苷类似物的口服制剂与抗pd1或抗pdl1单克隆抗体的组合治疗疾病或病症的方法
CN107073122A (zh) 恶性肿瘤的联合治疗
JP2009510114A (ja) 特定のrxrアゴニストによる癌治療
JP2015535291A (ja) 腎臓に障害のある対象におけるポマリドミドを用いる癌の治療
KR20240137001A (ko) 조혈 면역요법제(hit)로서의 il-12의 용도
KR20180088401A (ko) 3-(5-아미노-2-메틸-4-옥소-4h-퀴나졸린-3-일)-피페리딘-2,6-다이온을 사용한 주기 요법
Garnock-Jones Bendamustine: a review of its use in the management of indolent non-Hodgkin’s lymphoma and mantle cell lymphoma
CN1723029A (zh) 包括三氧化二砷的口服组合物的制剂及其使用方法
TW201642857A (zh) 以組合療法治療肝細胞癌
US20140357567A1 (en) Methods for treating cancers using oral formulations of cytidine analogs
Querfeld et al. Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma
US20260027056A1 (en) High surface-area lyophilized compositions comprising arsenic for oral administration in patients
US20240216465A1 (en) Method for treating refractory brain tumor
Addeo et al. Oxaliplatin/rituximab combination in the treatment of intermediate-low grade non-Hodgkin's lymphoma of elderly patients
HK40025426A (en) Combination cancer therapy
WO2015195786A2 (en) Methods for treating cancers using oral formulations of cytidine analogs
TR201901677T4 (tr) Sitidin analoglarının oral formülasyonları ve bunların kullanım yöntemleri.
NZ624323B2 (en) Methods for treating cancers using oral formulations of cytidine analogs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20131009

RJ01 Rejection of invention patent application after publication